Patients with lung cancer harboring a “single sensitizing uncommon mutation”, including G719X, S768I, and L861Q, usually had a good treatment response to EGFR TKI, although the response was generally still inferior to those harboring common sensitizing mutations as the report of Chiu et al. [13]. The gene discussed is EGFR; the disease is lung carcinoma.